Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) unable for cisplatin (CP)-based chemotherapy (CT): NIVOTAX TTCC study

被引：0

作者：

Iglesias Docampo, L. ^{[1
]}

Baste Rotllan, N. ^{[2
]}

Oliva Bernal, M. ^{[3
]}

Carral Maseda, A. ^{[4
]}

Perez Segura, P. ^{[5
]}

Medina Colmenero, A. ^{[6
]}

Cirauqui Cirauqui, B. ^{[7
]}

Arrazubi Arrula, V. ^{[8
]}

Martinez Trufero, J. ^{[9
]}

Gutierrez Calderon, V. ^{[10
]}

Garcia Castano, A. ^{[11
]}

Rubio-Casadevall, J. ^{[12
]}

Basterretxea, L. ^{[13
]}

Alvarez Cabellos, R. ^{[14
]}

del Barco Morillo, E. ^{[15
]}

Bruixola, G. ^{[16
]}

Flor, M. J. ^{[17
]}

Assaf Pastrana, J. D. ^{[18
]}

Caballero Daroqui, J. ^{[19
]}

Mesia Nin, R. ^{[20
]}

机构：

[1] Hosp Univ 12 Octubre, Med Oncol, Madrid, Spain

[2] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain

[3] Hosp Duran & Reynals, ICO Inst Catala Oncol Hospitalet, Med Oncol, Lhospitalet De Llobregat, Spain

[4] Hosp Univ Lucus Augusti HULA, Med Oncol, Lugo, Spain

[5] Hosp Clin Univ San Carlos, Med Oncol, IdISSC, Madrid, Spain

[6] Fdn Ctr Oncol Galicia, Med Oncol, La Coruna, Spain

[7] Hosp Badalona Germans Trias & Pujol, Med Oncol, ICO Inst Catala Oncol Badalona, Badalona, Barcelona, Spain

[8] Hosp Univ Navarra, Navarra Inst Hlth Res, Med Oncol, IdiSNA, Pamplona, Spain

[9] Hosp Univ Miguel Servet, Med Oncol, Zaragoza, Spain

[10] Hosp Reg Univ Malaga, Med Oncol, Malaga, Spain

[11] Hosp Univ Marques Valdecilla, Med Oncol, Santander, Spain

[12] ICO Girona Inst Catala Oncol Girona, Med Oncol, Girona, Spain

[13] Hosp Univ Donostia, Med Oncol, Donostia San Sebastian, Spain

[14] Hosp Univ Toledo, Med Oncol, Toledo, Spain

[15] Complejo Hosp Salamanca IBSAL, Med Oncol, Salamanca, Spain

[16] Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain

[17] Hosp Univ Virgen Rocio, Med Oncol, Seville, Spain

[18] Hosp Univ Vall dHebron, Med Oncol, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[19] Hosp Univ & Politecn La Fe, Med Oncol, Valencia, Spain

[20] Hosp Badalona Germans Trias & Pujol, Med Oncol, ICO Inst Catala Oncol Badalona, Badalona, Spain

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.932

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

871P

引用

页码：S624 / S624

页数：1

共 50 条

[21] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Bauman, Julie E.
Roe, Denise
Saba, Nabil F.
Bauman, Jessica Ruth
Kaczmar, John M.
Burtness, Barbara
Muzaffar, Jameel
Julian, Ricklie Ann
Wang, Steven
Bearelly, Shethal
Baker, Audrey
Steuer, Conor Ernst
Bhatia, Aarti K.
Giri, Anshu
Caulin, Carlos
Stabile, Laura P.
Centuori, Sara
Chung, Christine H.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[22] A phase II study of pemetrexed (P) plus gemcitabine (G) in patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
Pfister, D. G.
Haque, S.
Stambuk, H.
Lisa, D. M.
Shen, R.
Carlson, D.
Fury, M. G.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[23] A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer
Basaran, M
Bavbek, SE
Güllü, I
Demirelli, F
Sakar, B
Tenekeci, N
Altun, M
Yalçin, S
Onat, H
JOURNAL OF CHEMOTHERAPY, 2002, 14 (02) : 207 - 213
[24] Phase II trial evaluating axitinib for patients with uaresectable, recurrent, or metastatic (R/M) bead and neck squamous cell carcinoma (HNSCC)
Sacco, Assuntina Gesualda
Zhao, Lill
Carey, Thomas E.
Dobrosotskaya, Irina Y.
McHugh, Jonathan B.
Chepeha, Douglas Brian
Bradford, Carol Roasler
Wolf, Gregory T.
Prince, Mark E.
Moyer, Jeffrey
McKean, Erin Lynn
McLean, Scott A.
Malloy, Kelly M.
Spector, Matthew E.
Hogikyan, Norman D.
Urba, Susan
Ward, Brent
Worden, Francis P.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[25] Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
Gedlicka, C
Formanek, M
Selzer, E
Burian, M
Kornfehl, J
Fiebiger, W
Cartellieri, M
Marks, B
Kornek, GV
ONCOLOGY, 2002, 63 (02) : 145 - 150
[26] A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)
Ho, A. L.
Adkins, D. R.
Hanna, G. J.
Bruce, J.
Ahn, M. J.
Docampo, L. Iglesias
Kang, H.
Wong, D. J.
Psyrri, A.
Gillison, M.
Brana, I.
Liu, Y. C.
Hsieh, C. Y.
Hong, M. H.
Zhang, Z.
Balsara, B.
Saunders, A.
Hernandez, A. Gasco
Dale, S.
Haddad, R.
ANNALS OF ONCOLOGY, 2023, 34 : S1286 - S1287
[27] A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Dunn, Lara
Ho, Alan Loh
Eng, Juliana
Michel, Loren S.
Fetten, James Vincent
Warner, Elizabeth
Kriplani, Anuja
Zhi, Wanqing Iris
Ng, Kenneth K.
Haque, Sofia
Pfister, David G.
Sherman, Eric Jeffrey
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[28] Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC): A prospective phase II study
Gui, L.
Chen, X.
He, X.
Yang, J.
Liu, P.
Qin, Y.
Shi, Y-K.
ANNALS OF ONCOLOGY, 2023, 34 : S1609 - S1610
[29] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients (pts) with cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Bauman, J. E.
ANNALS OF ONCOLOGY, 2018, 29
[30] Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study
Schena, M
Barone, C
Birocco, N
Dongiovanni, D
Numico, G
Colantonio, I
Bertetto, O
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (03) : 271 - 276

← 1 2 3 4 5 →